Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Impact assessment TBM programme (Applied Biomedical Research) in Flanders

Publication date: 15 Dezember 2013 | Report language: NL

The Flemish programme on Applied Biomedical Research (TBM), funded by the agency for Innovation by Science and Technology (IWT), focuses on a particular niche in biomedical research: Research with a clear societal applicability but limited industrial interest. The programme, initiated in 2006, was oriented towards the development of new therapies, diagnosis and/or specific prevention of diseases. Technopolis Group conducted an impact assessment of the programme, which covered four different aspects:

  1. A thorough analysis of the entire project portfolio;
  2. An investigation of the results, effects and impact of the funded research projects;
  3. An evaluation of the organization, efficiency and effectiveness of the programme including the international position; and
  4. A proposal for relevant indicators to monitor the progress of the programme.

The three main conclusions derived by Technopolis Group were:

  1. The programme was unique in Flanders: There are little funding opportunities for this type of applied biomedical research. The programme helped Flanders to develop as a region for investigator-initiated clinical research;
  2. Many projects already produced applied results: More than 70% of the projects already applied (or expected to apply within 7 months) the results of their research to clinical practice (by means of a new diagnostic, therapy or preventive strategy). An important indicator of success of the programme is that follow up clinical trial studies have been started because of the results of the TBM-funded project;
  3. Projects mainly focused on the level of the individual patient instead of the level of the healthcare system: Many projects were single-centered studies, there were opportunities to increase dissemination of results to other centers (also beyond Flanders).